St. Jude Medical, Inc. (STJ) - NYSE
  • Oct. 21, 2014, 5:17 PM
    • St. Jude Medical (NYSE:STJ) declares $0.27/share quarterly dividend, in line with previous.
    • Forward yield 1.80%
    • Payable Jan 30; for shareholders of record Dec. 31; ex-div Dec. 29.
    | Oct. 21, 2014, 5:17 PM
  • Oct. 15, 2014, 8:30 AM
    • St. Jude Medical (NYSE:STJ) Q3 revenue growth by selected line item:
    • Leaders: Intl Neuromodulation: +14.3%; International Atrial Fibrillation: +11.5%; WW Atrial Fibrillation: +7.7%; U.S. Cardiovascular: +5.3%.
    • Laggards: International ICD: -3.0%; International Cardiac Rhythm Management: -2.2%; International Pacemakers: -1.3%; U.S. Neuromodulation: -1.3%.
    | Oct. 15, 2014, 8:30 AM
  • Oct. 15, 2014, 8:20 AM
    • St. Jude Medical (NYSE:STJ) Q3 results: Revenues: $1,372M (+2.5%); International: $706M (+2.0%); U.S.: $666M (+3.1%); WW Cardiac Rhythm Management (CRM): $688M (-0.3%); International CRM: $315M (-2.2%); U.S. CRM: $373M (+3.6%); WW ICD: $422M (+1.0%); Intl ICD: $160M (-3.0%); U.S. ICD: $262M (+3.6%); WW Pacemakers: $266M (+0.8%); Intl Pacemakers: $155M (-1.3%); U.S. Pacemakers: $111M (+3.7%); WW AF: $253M (+7.7%); Intl AF: $155M (+11.5%); U.S. AF: $98M (+2.1%); WW Cardiovascular: $324M (+2.2%); Intl Cardiovascular: $204M (+0.5%); U.S. Cardiovascular: $120M (+5.3%); WW Neuromodulation: $107M (+2.9%); Intl Neuromodulation:  $32M (+14.3%); U.S. Neuromodulation: $75M (-1.3%).
    • COGS: $412M (+7.0%); R&D Expense: $169M (-1.7%); SG&A Expense: $476M (+5.3%); Net Income: $238M (-9.2%); EPS: $0.82 (-8.9%); Quick Assets: $1,294M (+3.9%).
    • Gross Profit: $960M (+0.7%); COGS: 30.0% (+4.4%); Gross Margin: 70.0% (-1.8%); Operating Profit: $315M (-4.3%); Operating Earnings Yield: 23.0% (-6.6%); Net Earnings Yield: 17.3% (-11.4%).
    • 2014 guidance: Revenues: $5.568B - 5.648B from $5.64B - 5.76B; EPS: $3.97 - 3.99 from $3.96 - 4.01.
    • Q4 guidance: Revenues: $1.385B - 1.465B; EPS: $1.02 - 1.04.
    | Oct. 15, 2014, 8:20 AM | 2 Comments
  • Oct. 15, 2014, 7:34 AM
    • St. Jude Medical (NYSE:STJ): Q3 EPS of $0.97 beats by $0.01.
    • Revenue of $1.37B (+2.2% Y/Y) misses by $10M.
    • Shares +0.15% PM.
    | Oct. 15, 2014, 7:34 AM
  • Oct. 14, 2014, 5:30 PM
  • Oct. 1, 2014, 6:23 PM
    • ST. Jude Medical (STJ +0.4%) will report Q3 results on Wednesday, October 15 before the open. The conference call will begin at 6:30 am CT.
    • Consensus view is EPS of $0.96 on revenues of $1.39B.
    | Oct. 1, 2014, 6:23 PM
  • Oct. 1, 2014, 4:37 PM
    • St. Jude Medical (STJ +0.4%) will report Q3 results on October 15 before the open. The conference call will begin at 7:00 am CT.
    • Consensus view is EPS of $0.96 on revenues of $1.39B.
    | Oct. 1, 2014, 4:37 PM
  • Oct. 1, 2014, 10:05 AM
    • In response to the ever-increasing risk of security breaches, the FDA issues final guidance for device makers entitled, "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices." The agency recommends that device manufacturers consider cybersecurity risks at part of the design and development of their products and submit documentation to the FDA about the risks identified and the controls in place to mitigate them. The agency also recommends that companies submit their plans for patches and upgrades to device operating systems and medical software.
    • The agency will hold a public workshop on October 21, 2014 to discuss how all the constituency groups can work together to improve cybersecurity in medical devices and protect the public health.
    • ETFs: IBB, BIB, IRY, IXJ, BIS, DRGS
    • Some related tickers: (MDT -0.2%)(BSX -0.9%)(STJ -0.3%)(ABT -0.6%)(JNJ -1.4%)(OTCQX:RHHBY +0.1%)
    | Oct. 1, 2014, 10:05 AM | 1 Comment
  • Sep. 15, 2014, 11:51 AM
    • The FDA and EC issue 510(k) and CE Mark clearances, respectively, to St. Jude Medical (STJ -1.1%) for its Optis Integrated System, which is directly installed into a hospital's cardiac catheterization laboratory. It fully integrates optical coherence tomography (OCT) and fractional flow reserve  in percutaneous coronary intervention (PCI) workflow.
    • It is the first PCI optimization system to offer OCT and angiography co-registration. It supports procedural decisions by providing high-resolution 3D OCT views of coronary anatomy while mapping the exact location of the current view via angiogram.
    • It also integrates the company's PressureWire fractional flow reserve measurement technology which provides hemodynamic information during PCI.
    | Sep. 15, 2014, 11:51 AM
  • Aug. 27, 2014, 12:46 PM
    • The FDA notifies St. Jude Medical (STJ +0.1%) that the issues cited in its warning letter regarding its Plano, TX manufacturing facility have been resolved. The agency issued the letter on June 26, 2009 after an on-site inspection identified cGMP non-conformities.
    | Aug. 27, 2014, 12:46 PM
  • Jul. 29, 2014, 6:21 PM
    • St. Jude Medical (NYSE:STJ) declares $0.27/share quarterly dividend, in line with previous.
    • Forward yield 1.64%
    • Payable Oct. 31; for shareholders of record Sept. 30; ex-div Sept. 26.
    | Jul. 29, 2014, 6:21 PM
  • Jul. 22, 2014, 8:53 AM
    • St. Jude Medical's (NYSE:STJ) Flexibility Ablation Catheter achieves CE Mark clearance in Europe. The product has a flexible tip that reduces complications associated with ablation procedures by conforming to the cardiac anatomy and reducing the amount of pressure to the cardiac wall.
    | Jul. 22, 2014, 8:53 AM
  • Jul. 16, 2014, 8:21 AM
    • St. Jude Medical (NYSE:STJ) Q2 results: Total Revenues: $1,448M (+3.2%); ICD: $462M (+1.8%); Pacemakers: $271M (+2.7%); AF: $257M (+8.4%); Cardiovascular: $351M (+3.2%); Neuromodulation: $107M (-0.9%).
    • COGS: $433M (+13.4%); R&D Expense: $178M (+2.9%); SG&A Expense: $523M (+7.0%); Net Income: $270M (+134.8%); EPS: $0.93 (+132.5%); Quick Assets: $1,580M (+29.5%).
    • Gross Profit: $1,015M (-0.6%); COGS%: 29.9% (+9.8%); Gross Margin%: 70.1% (-3.7%); Operating Profit: $314M (-12.5%); Operating Earnings Yield: 21.7% (-15.3%); Net Earnings Yield: 18.6% (+127.5%).
    • 2014 EPS guidance raised to $3.96 - 4.01 from $3.76 - 3.81 on revenues of $5.64B - 5.76B.
    | Jul. 16, 2014, 8:21 AM
  • Jul. 16, 2014, 7:31 AM
    • St. Jude Medical (NYSE:STJ): Q2 EPS of $1.02 beats by $0.02.
    • Revenue of $1.45B (+3.6% Y/Y) beats by $10M.
    | Jul. 16, 2014, 7:31 AM
  • Jul. 15, 2014, 5:30 PM
    | Jul. 15, 2014, 5:30 PM | 5 Comments
  • Jul. 14, 2014, 9:58 AM
    • St. Jude Medical (STJ -0.8%) enters into a definitive agreement to acquire privately-held NeuroTherm, a maker of interventional pain management therapies, for ~$200M in cash. The company expects to conclude the transaction in late Q3. NeuroTherm will add $10M - 15M to STJ's top-line sales in 2014.
    • NeuroTherm's technology utilizes radiofrequency ablation (RFA) to treat spinal pain.
    | Jul. 14, 2014, 9:58 AM
Company Description
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. It operates through two operating... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States